抗小鼠PD-1单抗(RMP1-14/RMP1-14.1)参考文献与肿瘤免疫实验应用

在肿瘤免疫学、自体免疫疾病及免疫检查点抑制剂研发中，程序性死亡受体1（PD-1）及其配体（PD-L1/PD-L2）相互作用的阻断实验是评估T细胞杀伤活性与肿瘤免疫逃逸机制的基础。克隆号为 RMP1-14 的抗小鼠PD-1单克隆抗体作为经典的阻断型抗体，被广泛用于小鼠模型的体内（In Vivo）PD-1/PD-L1信号传导阻断以及体外（In Vitro）细胞免疫分析。

本文汇总了使用克隆号 RMP1-14/RMP1-14.1 抗小鼠PD-1抗体发表的20篇代表性SCI论文，并详细解析 Syd Labs 体内实验级重组抗小鼠PD-1单抗（货号：PA007162.r2a）的技术参数与适用场景。

抗小鼠PD-1单抗（克隆号RMP1-14）20篇精选参考文献

以下为科研人员在PD-1/PD-L1通路阻断、联合免疫治疗、T细胞功能调控及肿瘤微环境研究中发表的高质量学术文献：

1. PD-L1/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior
2. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration
3. Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain
4. Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
5. Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy
6. Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework
7. Targeting PD-L2/RGMb overcomes microbiome-related immunotherapy resistance
8. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
9. Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells
10. Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells
11. Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma
12. Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity
13. Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells
14. Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
15. Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells
16. Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues
17. Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells
18. Immune receptor inhibition through enforced phosphatase recruitment
19. Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs
20. Myeloid Antigen-Presenting Cell Niches Sustain Antitumor T Cells and License PD-1 Blockade via CD28 Costimulation

Syd Labs 重组抗小鼠PD-1抗体（克隆号RMP1-14.1）优势特点

Syd Labs 体内实验级重组抗小鼠PD-1单抗（克隆号RMP1-14.1），大鼠IgG2a Kappa（In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Rat IgG2a Kappa，货号：PA007162.r2a）采用哺乳动物表达系统重组生产。其可变区序列与传统大鼠抗小鼠PD-1抗体（克隆号：RMP1-14）保持高度一致，确保了实验结果的可重复性与高特异性。

• 表达系统：哺乳动物细胞重组表达体系（无动物源杂质干扰）；
• 亚型匹配：大鼠 IgG2a, kappa（Rat IgG2a, kappa）；
• 应用范围：
  • 体内（In Vivo）动物模型中的PD-1/PD-L1信号通路阻断与免疫治疗联合用药研究；
  • 免疫组织化学（IHC）及流式细胞术（FC/FACS）检测；
  • 体外（In Vitro）T细胞激活与功能分析。

Syd Labs 强烈呼吁珍爱生命、减少使用动物生产抗体！倡导使用重组技术制备功能性抗体，共同推动科研动物福利与高可重复性学术研究。

技术咨询与官方授权渠道

如果您对 Syd Labs 重组抗体有任何技术问题，需要索取详细规格说明书，或者申请 Syd Labs 中国代理商 授权资质、确认代理商真伪及举报非正规渠道，欢迎随时与我们联系：

• 企业微信：duozhaozhao2024
• 联系电话：18162581039（龙经理）